Drug intelligence / Profile preview

NAI-Acne gel

Development stage: Unknown
Lead developer: NAICONS
Modality: Small Molecules
Administration: Topical

Overview

NAI-Acne gel is a topical investigational drug developed by NAICONS Srl for the treatment of moderate to severe acne vulgaris. Formulated as a 3% gel for twice-daily application, it acts as an inhibitor of Eukaryotic Elongation Factor 1-Alpha 1 (EEF1A1), a protein involved in protein synthesis that represents a novel target in dermatology. The drug has been evaluated in a Phase 2, placebo-controlled clinical trial (Study NAI-003) in Slovakia, focusing on efficacy measures such as inflammatory and total lesion counts, the Investigator's Global Assessment (IGA), and the Cardiff Acne Disability Index (CADI). Its development status is currently listed as pending regulatory approval.

Other names: NAI-Acne gelNAI-Acne 3% gel

Targets

EEF1A1 (Elongation Factor 1 Alpha)

Beyond the preview

Go deeper on NAI-Acne gel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NAI-Acne gel.

Explore the full profile